Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 5/2018

19.03.2018 | Original Article

Predictive significance of breast-specific gamma imaging for upstaging core-needle biopsy-detected ductal carcinoma in situ to invasive cancer

verfasst von: Jang Yoo, Bom Sahn Kim, Hai-Jeon Yoon

Erschienen in: Annals of Nuclear Medicine | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

We evaluated the significance of breast-specific gamma imaging (BSGI) for determination of upstaging to invasive cancer from preoperative ductal carcinoma in situ (DCIS).

Methods

This study enrolled 168 patients with 175 breast lesions diagnosed as DCIS on core-needle biopsy that subsequently underwent preoperative BSGI between September 2011 and October 2017. Both qualitative and quantitative analyses using tumor-to-normal background ratio (TNR) and coefficient of variation (COV) were performed, and the predictive significance for upstaging to invasive cancer was investigated. We also sought to identify clinicopathological factors associated with upstaging and their relation to BSGI findings.

Results

Fifty-eight lesions (33.1%) were confirmed to be invasive breast cancer after the final surgical approach. On univariate analysis, tumor size based on ultrasonography (US), hormone status, histologic grade, Breast Imaging Reporting and Data System category, comedo-necrosis, Ki-67 expression, and BSGI findings were associated with upstaging to invasive cancer. Tumor size > 2.0 cm (p = 0.005), Ki-67 expression > 8% (p < 0.001), qualitative BSGI findings (p = 0.020), and COV > 30.44 (p = 0.022) were independently associated with upstaging after multiple regression analysis.

Conclusion

BSGI is a useful imaging modality for predicting upstaging to invasive breast cancer from DCIS on core-needle biopsy in conjunction with US tumor size and Ki-67 expression.
Literatur
1.
Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–41.CrossRefPubMed
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed
3.
Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg. 2008;247:315–9.CrossRefPubMed
4.
Houssami N, Ciatto S, Ellis I, Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109(3):487–95.CrossRefPubMed
5.
O’Flynn EA, Morel JC, Gonzalez J, Dutt N, Evans D, Wasan R, et al. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. Clin Radiol. 2009;64(2):178–83.CrossRefPubMed
6.
Sauer G, Deissler H, Strunz K, Helms G, Remmel E, Koretz K, et al. Ultrasound-guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification. Br J Cancer. 2005;92(2):231–5.CrossRefPubMed
7.
Kim BS. Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with dense breast: a comparative study with MRI. Ann Nucl Med. 2012;26:131–7.CrossRefPubMed
8.
Yoon HJ, Kim Y, Chang KT, Kim BS. Prognostic value of semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer. Ann Nucl Med. 2015;29:553–60.CrossRefPubMed
9.
Kim J, Han W, Lee JW, You JM, Shin HC, Ahn SK, et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast. 2012;21:641–5.CrossRefPubMed
10.
Lee JW, Han W, Ko E, Cho J, Kim EK, Jung SY, et al. Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol. 2008;98:15–20.CrossRefPubMed
11.
Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16–20.CrossRefPubMed
12.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMed
13.
Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res. 2014;16:R35.CrossRefPubMedPubMedCentral
14.
Goldsmith SJ, Parsons W, Guiberteau MJ, Stern LH, Lanzowsky L, Weigert J, et al. SNM practice guideline for breast scintigraphy with breast-specific γ-cameras 1.0. J Nucl Med Technol. 2010;38:219–24.CrossRefPubMed
15.
Kim BS, Moon BI, Cha ES. A comparative study of breast-specific gamma imaging with the conventional imaging modality in breast cancer patients with dense breasts. Ann Nucl Med. 2012;26:823–9.CrossRefPubMed
16.
Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology. 2008;247:651–7.CrossRefPubMed
17.
Yoo J, Yoon HJ, Kim BS. Prognostic value of primary tumor SUVmax on F-18 FDG PET/CT compared with semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer. Ann Nucl Med. 2017;31:19–28.CrossRefPubMed
18.
Dillon MF, McDermott EW, Quinn CM, O’Doherty A, O’Higgins N, Hill AD. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J Surg Oncol. 2006;93:559–63.CrossRefPubMed
19.
Deurloo EE, Sriram JD, Teertstra HJ, Loo CE, Wesseling J, Rutgers EJ, et al. MRI of the breast in patients with DCIS to exclude the presence of invasive disease. Eur Radiol. 2012;22:1504–11.CrossRefPubMed
20.
Shigematsu H, Kadoya T, Masumoto N, Matsuura K, Emi A, Kajitani K, et al. Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy. Clin Breast Cancer. 2014;14:358–64.CrossRefPubMed
21.
Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260:119–28.CrossRefPubMed
22.
Chan MY, Lim S. Predictors of invasive breast cancer in ductal carcinoma in situ initially diagnosed by core biopsy. Asian J Surg. 2010;33:76–82.CrossRefPubMed
23.
Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539–52.CrossRefPubMedPubMedCentral
24.
Yoon HJ, Kim Y, Kim BS. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ. Eur Radiol. 2015;25:3648–58.CrossRefPubMed
25.
Henriksson E, Kjellen E, Wahlberg P, Ohlsson T, Wennerberg J, Brun E. 2-Deoxy-2-[18F] fluoro-d-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res. 2007;27:2155–9.PubMed
26.
Van Baardwijk A, Bosmans G, Van Suylen RJ, Van Kroonenburgh M, Hochstenbag M, Geskes G, et al. Correlation of intra-tumoral heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87:55–8.CrossRefPubMed
27.
Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumoral heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.CrossRefPubMedPubMedCentral
28.
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–502.CrossRefPubMed
29.
Owaki T, Kijima Y, Yoshinaka H, Uenosono Y, Yoshioka T, Natsugoe S, et al. Ductal carcinoma in situ of the breast detected by [F-18] fluorodeoxyglucose positron emission tomography. Breast Cancer. 2006;13:210–3.CrossRefPubMed
30.
Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001;67:513–9.PubMed
31.
McMasters KM, Chao C, Wong SL, Martin RCG III, Edwards MJ. Sentinel lymph node biopsy in patients with ductal carcinoma in situ: a proposal. Cancer. 2002;95:15–20.CrossRefPubMed
32.
Siziopikou KP. Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med. 2013;137:462–6.CrossRefPubMed
33.
Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138:309–13.CrossRefPubMed
34.
Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;4:563–6.CrossRef
35.
Kuhn KJ, Rapelyea JA, Torrente J, Teal CB, Brem RF. Comparative diagnostic utility of low-dose breast-specific gamma imaging to current clinical standard. Breast J. 2016;22:180–8.CrossRefPubMed
Metadaten
Titel
Predictive significance of breast-specific gamma imaging for upstaging core-needle biopsy-detected ductal carcinoma in situ to invasive cancer
verfasst von
Jang Yoo
Bom Sahn Kim
Hai-Jeon Yoon
Publikationsdatum
19.03.2018
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 5/2018
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1251-2

Weitere Artikel der Ausgabe 5/2018

Annals of Nuclear Medicine 5/2018 Zur Ausgabe

Original Article

CT-based attenuation correction and resolution compensation for I-123 IMP brain SPECT normal database: a multicenter phantom study

Original Article

Artificial neural network retrained to detect myocardial ischemia using a Japanese multicenter database

Original Article

Implementation of GPU accelerated SPECT reconstruction with Monte Carlo-based scatter correction

Original Article

Quantitative evaluation of the tracer distribution in dopamine transporter SPECT for objective interpretation

Short Communication

FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)

Original Article

Diagnostic value of quantitative assessment of cardiac 18F-fluoro-2-deoxyglucose uptake in suspected cardiac sarcoidosis